Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LP-003 in adolescents with allergic diseases
NCT07148557Phase 2Active, not recruiting
- Sponsor
- LongBio Pharma
- Start
- Oct 2025
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of LP-003 in allergic disease, sponsored by LongBio Pharma. Started Oct 2025; status: active, not recruiting.
02
Drugs
LP-003
03
Conditions
allergic disease
Beyond the preview
Go deeper on NCT07148557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07148557.